OTCMKTS:PROT - Stromacel Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0170 0.00 (0.00 %)
(As of 05/21/2019 04:54 AM ET)
Previous Close$0.0180
Today's Range$0.0085 - $0.0180
52-Week Range$0.0050 - $0.07
Volume20,500 shs
Average Volume12,288 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.

Receive PROT News and Ratings via Email

Sign-up to receive the latest news and ratings for PROT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:PROT



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Stromacel (OTCMKTS:PROT) Frequently Asked Questions

What is Stromacel's stock symbol?

Stromacel trades on the OTCMKTS under the ticker symbol "PROT."

Has Stromacel been receiving favorable news coverage?

Headlines about PROT stock have been trending somewhat negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stromacel earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Stromacel's key competitors?

Who are Stromacel's key executives?

Stromacel's management team includes the folowing people:
  • Mr. Michael Cohen, Founder, Chairman, CEO, Pres & COO (Age 52)
  • Mr. Steven Byle, CTO & Director (Age 51)
  • Mr. Jason B. Isaacs, Sec. (Age 47)
  • Ms. Jaci Mandil, Chief Exec. Officer of Proteoderm

How do I buy shares of Stromacel?

Shares of PROT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stromacel's stock price today?

One share of PROT stock can currently be purchased for approximately $0.0170.

What is Stromacel's official website?

The official website for Stromacel is http://stromacel.com/.

How can I contact Stromacel?

Stromacel's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116.

MarketBeat Community Rating for Stromacel (OTCMKTS PROT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Stromacel and other stocks. Vote "Outperform" if you believe PROT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel